Page last updated: 2024-09-05

lasofoxifene and Coronary Disease

lasofoxifene has been researched along with Coronary Disease in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Armstrong, RA; Cummings, SR; Delmas, PD; Eastell, R; Ensrud, K; Goldstein, S; Kendler, D; LaCroix, AZ; Lee, A; Neven, P; Powles, T; Reid, DM; Sriram, U; Thompson, DD; Thompson, J; Vukicevic, S; Zanchetta, J	1
Becker, C	1
Armstrong, R; Barrett-Connor, E; Cauley, J; Cummings, S; Eastell, R; Ensrud, K; LaCroix, A; Reid, DM; Thompson, DD; Thompson, JR; Vukicevic, S; Welty, F	1

Trials

2 trial(s) available for lasofoxifene and Coronary Disease

Article	Year
Lasofoxifene in postmenopausal women with osteoporosis. The New England journal of medicine, 2010, Feb-25, Volume: 362, Issue:8 Topics: Aged; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tetrahydronaphthalenes; Venous Thromboembolism	2010
Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. Circulation, 2010, Oct-26, Volume: 122, Issue:17 Topics: Aged; Aged, 80 and over; Breast Neoplasms; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Endpoint Determination; Female; Follow-Up Studies; Fractures, Bone; Humans; Incidence; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Receptors, Estrogen; Risk Factors; Stroke; Tetrahydronaphthalenes; Treatment Outcome	2010

Article

Year

Lasofoxifene in postmenopausal women with osteoporosis.

The New England journal of medicine, 2010, Feb-25, Volume: 362, Issue:8

Topics: Aged; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tetrahydronaphthalenes; Venous Thromboembolism

2010

Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.

Circulation, 2010, Oct-26, Volume: 122, Issue:17

Topics: Aged; Aged, 80 and over; Breast Neoplasms; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Endpoint Determination; Female; Follow-Up Studies; Fractures, Bone; Humans; Incidence; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Receptors, Estrogen; Risk Factors; Stroke; Tetrahydronaphthalenes; Treatment Outcome

2010

Other Studies

1 other study(ies) available for lasofoxifene and Coronary Disease

Article	Year
Another selective estrogen-receptor modulator for osteoporosis. The New England journal of medicine, 2010, Feb-25, Volume: 362, Issue:8 Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism	2010

Article

Year

Another selective estrogen-receptor modulator for osteoporosis.

The New England journal of medicine, 2010, Feb-25, Volume: 362, Issue:8

Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism

2010